NCT03428802 2026-04-03
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
Clinical Trials
218 trialsNCT02873962 2026-04-01
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07241091 2026-03-30
SurgiPerito Trial: High-Purity Type-I Collagen for Peritoneal Reconstruction After Cytoreductive Surgery
Adichunchanagiri Institute of Medical Sciences, B G Nagara
Phase NA Completed
NCT04905082 2026-03-24
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
City of Hope Medical Center
Phase NA Active not recruiting
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03367247 2026-03-10
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
Dana-Farber Cancer Institute
Phase NA Completed
NCT04024254 2026-03-04
A Study of Serum Folate Levels in Patients Treated With Olaparib
Rush University Medical Center
Phase 4 Completed
NCT03763838 2026-02-05
Acupressure for Fatigue in Ovarian Cancer Survivors
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04670068 2025-12-22
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02364713 2025-12-11
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Phase 2 Terminated
NCT04339140 2025-12-11
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT02326064 2025-12-02
TORCH
Centre Hospitalier Departemental Vendee
Completed
NCT02068794 2025-11-18
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Mayo Clinic
Phase 1/2 Active not recruiting
NCT03188432 2025-10-21
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT05708703 2025-09-16
Assessing the Time Demands of Cancer
Masonic Cancer Center, University of Minnesota
Active not recruiting
NCT03085225 2025-09-04
TRAMUNE
Institut Bergonié
Phase 1 Completed
NCT05708924 2025-08-14
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT04611126 2025-08-12
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
Phase 1/2 Terminated
NCT06048367 2025-08-03
CNSI-Fe(II)
Sichuan Enray Pharmaceutical Sciences Company
Phase 1 Completed
NCT02821793 2025-07-01
PRIORITY
Institut Bergonié
Completed
NCT04608409 2025-06-29
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
University of Kentucky
Phase 1 Completed
NCT02650986 2025-06-17
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT03783949 2025-06-11
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT04019288 2025-06-11
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03326713 2025-05-28
GRACE
Rutgers, The State University of New Jersey
Phase NA Completed
NCT03456700 2025-05-08
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
Mayo Clinic
Phase 2 Terminated
NCT02569957 2025-05-04
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT03054298 2025-04-29
CAR T Cells in Mesothelin Expressing Cancers
University of Pennsylvania
Phase 1 Completed
NCT03610490 2025-04-17
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03585764 2025-03-26
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Pennsylvania
Phase 1 Terminated
NCT04696276 2025-03-26
ERAS
University of West Attica
Phase NA Completed
NCT03164980 2025-03-20
COMPASS
North Eastern German Society of Gynaecological Oncology
Phase 4 Terminated
NCT04492007 2025-02-03
PRISMS
UNC Lineberger Comprehensive Cancer Center
Phase NA Completed
NCT03154190 2025-01-24
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
Phase NA Completed
NCT03994653 2025-01-20
CLOCS
Imperial College London
Completed
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT00170573 2024-12-16
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Phase 2 Completed
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT04525183 2024-11-15
REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue
Dana-Farber Cancer Institute
Phase NA Completed
NCT00170625 2024-11-12
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Phase 1/2 Completed
NCT03318900 2024-11-07
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03246074 2024-10-24
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT04927013 2024-10-03
Connecting Families to Overcome Ovarian Cancer
Emory University
Phase NA Completed
NCT04377087 2024-08-20
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Terminated
NCT03154281 2024-08-01
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
Avera McKennan Hospital & University Health Center
Phase 1 Completed
NCT00194714 2024-06-06
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
University of Washington
Phase 1/2 Completed
NCT00445965 2024-04-04
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02923739 2024-03-13
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated